YadA inhibitors belong to a unique class of chemical compounds designed to target the YadA protein, which is primarily found in certain pathogenic bacteria. YadA, short for "Yersinia adhesin A," is a surface protein expressed by bacteria belonging to the Yersinia genus, such as Yersinia enterocolitica and Yersinia pseudotuberculosis. This protein plays a crucial role in the initial stages of host-pathogen interactions, as it functions as an adhesin and invasin, allowing the bacterium to adhere to host cells and facilitate its entry into the host organism. YadA is a significant virulence factor and contributes to the pathogenicity of these bacteria, making it an attractive target for the development of inhibitors.
YadA inhibitors are designed to disrupt the interaction between the YadA protein and host cells. These chemical compounds are typically small molecules that can bind to specific regions of the YadA protein, thereby blocking its adhesion to host cell receptors. By inhibiting this crucial step in the infection process, YadA inhibitors impedes the ability of Yersinia bacteria to establish infections and cause diseases in the host. The development of YadA inhibitors represents a promising avenue in the field of anti-infective research, as it offers a strategy to combat Yersinia infections at their root, by targeting a fundamental aspect of the pathogen's virulence. This class of compounds is the subject of ongoing research aimed at better understanding their mechanism of action and optimizing their effectiveness in combating Yersinia-associated diseases.
Items 1 to 10 of 23 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor targeting the PI3K/Akt pathway, suppressing downstream signaling cascades that regulate YadA expression. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL tyrosine kinase, used in leukemia | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Selective estrogen receptor modulator (SERM) to block breast cancer | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Blocks PI3K activity, disrupting the PI3K/Akt pathway, ultimately leading to inhibition of YadA expression and function. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Protease inhibitor, used in HIV therapy to block viral replication. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor impacting the mTOR pathway, which regulates protein translation and YadA synthesis, resulting in inhibition. | ||||||
A66 | 1166227-08-2 | sc-364394 sc-364394A | 5 mg 50 mg | $255.00 $1455.00 | ||
Akt inhibitor disrupting the PI3K/Akt pathway, consequently down-regulating YadA expression through Akt inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multikinase inhibitor targeting Raf, VEGFR, and PDGFR in cancer therapy. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
Allosteric Akt inhibitor, blocking the PI3K/Akt pathway and hindering YadA expression by inhibiting downstream signaling. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Proton pump inhibitor, reduces gastric acid secretion for ulcers and GERD. | ||||||